SCHEMBL286598

SCHEMBL286598

COC(=O)c1cc(N)nn1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
KDM4E B2RXH2 5/20 0.40
HPGD P15428 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
F2 P00734 1/20 0.36
ATAD2 Q6PL18 1/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL286597 0.98 CA12 (0.41) CA12CA1CA2CA9KDM4E
SCHEMBL29824612 0.88 HPGD (0.36) CA12CA1CA2CA9KDM4E
SCHEMBL17662694 0.85 KDM4E (0.36) CA12CA1CA2CA9KDM4E
SCHEMBL17796531 0.81 KDM4E (0.40) CA12CA1CA2CA9KDM4E
SCHEMBL286585 0.81 LMNA (0.50) KDM4EHPGDL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL26241947 0.80 KDM4E (0.40) KDM4EL3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL15273734 0.80 MEN1 (0.43) CA12CA1CA2CA9KDM4E
Hydrochloric Acid SCHEMBL286584 0.80 LMNA (0.49) KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL69696 0.79 MEN1 (0.44) CA12CA1CA2CA9KDM4E
SCHEMBL975064 0.79 SMN1; SMN2 (0.47) CA12CA1CA2CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 US disclosed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 US disclosed
EP-4551549-A1 NLRP3 INHIBITORS Kodiak Sciences Inc. (US) 2025-05-14 EP disclosed
EP-4522604-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2025-03-19 EP disclosed
US-20250019380-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-01-16 US disclosed
US-20240343710-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. 2024-10-17 US disclosed
WO-2024178127-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-08-29 WO disclosed
EP-4370124-A1 PI3Ka INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-05-22 EP disclosed
US-20240124455-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS JINGRUI BIOPHARMA CO., LTD. (CN) 2024-04-18 US disclosed
CN-117881683-A PI3K alpha inhibitors and methods of use thereof 传达治疗有限公司 2024-04-12 CN disclosed
WO-2004099155-A2 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed
US-6740647-B1 AMIDINES AND HYDROXYAMIDINE DERIVATIVES ABBOTT GMBH & CO., KG (DE) 2004-05-25 US disclosed
EP-0722446-B1 DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS PHARMACIA ITALIA SPA (IT) 2002-12-11 EP disclosed
US-5753629-A AMINO ACID DERIVATIVE ANTIBIOTICS; VIRICIDES PHARMACIA S.P.A. (IT) 1998-05-19 US disclosed
CN-1131946-A Distamycin A analogues as antitumour or antiviral agents PHARMACIA SPA (IT) 1996-09-25 CN disclosed
EP-0722446-A1 DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 1996-07-24 EP disclosed
WO-1996005196-A1 DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS PHARMACIA S.P.A. (IT) 1996-02-22 WO disclosed
US-4795817-A FUNGICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-01-03 US disclosed
WO-1985001732-A1 8-SUBSTITUTED PYRAZOLOPENTATHIEPINS AND RELATED COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-25 WO disclosed
EP-0138622-A2 8-substituted pyrazolopentathiepins and related compounds E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124455-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS TP53, TK2, TOP2A CA12 825/4885CA1 2125/4885CA2 1674/4885
US-20250019380-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD CA12 4616/4885CA1 4214/4885CA2 3500/4885
US-20240343710-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PARP1, PARP11, PARP12 CA12 3521/4885CA1 3319/4885CA2 3890/4885
US-20250388568-A1 NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 CA12 4678/4885CA1 3531/4885CA2 2012/4885
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus NHERF1, ZC3HAV1, SARS1 CA12 1289/4885CA1 1898/4885CA2 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.